['patient_ID', 'study', 'pCR', 'RFS', 'DFS', 'radio', 'surgery', 'chemo', 'hormone', 'posOutcome', 'Basal', 'Her2', 'LumA', 'LumB', 'Normal']
study_12093_GPL96_all-bmc15 136
protocol 1 136
pCR=-  RFS=-  DFS=116=85.3%  posOutcome=116=85.3%
Basal=0=0.0%  Her2=1=0.7%  LumA=103=75.7%  LumB=31=22.8%  Normal=1=0.7%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1


study_1379_GPL1223_all-bmc15 60
protocol 1 60
pCR=-  RFS=-  DFS=32=53.3%  posOutcome=32=53.3%
Basal=0=0.0%  Her2=1=1.7%  LumA=58=96.7%  LumB=0=0.0%  Normal=1=1.7%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1


study_16391_GPL570_all-bmc15 48
protocol 1 2
pCR=-  RFS=2=100.0%  DFS=-  posOutcome=2=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=2=100.0%  LumB=0=0.0%  Normal=0=0.0%
surgery 1
hormone 1
anti_estrogen 1.0
letrozole 1.0
aromatase_inhibitor 1.0
neoadjuvant_or_adjuvant adj
estrogen_receptor_blocker_and_stops_production 1.0
treatment_protocol_number 1

protocol 2 3
pCR=-  RFS=2=66.7%  DFS=-  posOutcome=2=66.7%
Basal=0=0.0%  Her2=0=0.0%  LumA=2=66.7%  LumB=1=33.3%  Normal=0=0.0%
surgery 1
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 2

protocol 3 16
pCR=-  RFS=12=75.0%  DFS=-  posOutcome=12=75.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=10=62.5%  LumB=6=37.5%  Normal=0=0.0%
surgery 2
radio 1
hormone 1
anti_estrogen 1.0
letrozole 1.0
aromatase_inhibitor 1.0
neoadjuvant_or_adjuvant adj
estrogen_receptor_blocker_and_stops_production 1.0
treatment_protocol_number 3

protocol 4 9
pCR=-  RFS=8=88.9%  DFS=-  posOutcome=8=88.9%
Basal=0=0.0%  Her2=0=0.0%  LumA=6=66.7%  LumB=3=33.3%  Normal=0=0.0%
surgery 2
radio 1
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 4

protocol 6 1
pCR=-  RFS=1=100.0%  DFS=-  posOutcome=1=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=100.0%  LumB=0=0.0%  Normal=0=0.0%
surgery 1
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant mixed
treatment_protocol_number 6
chemo 1

protocol 7 17
pCR=-  RFS=13=76.5%  DFS=-  posOutcome=13=76.5%
Basal=0=0.0%  Her2=1=5.9%  LumA=10=58.8%  LumB=6=35.3%  Normal=0=0.0%
surgery 1
radio 1
hormone 1
anti_estrogen 1.0
letrozole 1.0
aromatase_inhibitor 1.0
neoadjuvant_or_adjuvant mixed
estrogen_receptor_blocker_and_stops_production 1.0
treatment_protocol_number 7
chemo 1


study_16446_GPL570_all-bmc15 114
protocol 1 114
pCR=16=14.0%  RFS=-  DFS=89=78.1%  posOutcome=89=78.1%
Basal=81=71.1%  Her2=19=16.7%  LumA=1=0.9%  LumB=7=6.1%  Normal=6=5.3%
neoadjuvant_or_adjuvant mixed
anthracycline 1.0
treatment_protocol_number 1
epirubicin 1.0
chemo 1


study_17705_GPL96_JBI_Tissue_BC_Tamoxifen-bmc15 103
protocol 1 103
pCR=-  RFS=85=82.5%  DFS=-  posOutcome=85=82.5%
Basal=0=0.0%  Her2=3=2.9%  LumA=80=77.7%  LumB=17=16.5%  Normal=3=2.9%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1


study_17705_GPL96_MDACC_Tissue_BC_Tamoxifen-bmc15 195
protocol 1 195
pCR=-  RFS=142=72.8%  DFS=-  posOutcome=142=72.8%
Basal=4=2.1%  Her2=0=0.0%  LumA=156=80.0%  LumB=32=16.4%  Normal=3=1.5%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1


study_19615_GPL570_all-bmc15 110
protocol 1 23
pCR=-  RFS=20=87.0%  DFS=-  posOutcome=20=87.0%
Basal=15=65.2%  Her2=2=8.7%  LumA=2=8.7%  LumB=4=17.4%  Normal=0=0.0%
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
chemo 1

protocol 10 1
pCR=-  RFS=1=100.0%  DFS=-  posOutcome=1=100.0%
Basal=0=0.0%  Her2=1=100.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
doxorubicin 1.0
anti_HER2 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 10
chemo 1

protocol 11 2
pCR=-  RFS=2=100.0%  DFS=-  posOutcome=2=100.0%
Basal=1=50.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=1=50.0%  Normal=0=0.0%
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
fluorouracil 1.0
cyclophosphamide 1.0
treatment_protocol_number 11
chemo 1

protocol 12 16
pCR=-  RFS=15=93.8%  DFS=-  posOutcome=15=93.8%
Basal=0=0.0%  Her2=0=0.0%  LumA=11=68.8%  LumB=5=31.2%  Normal=0=0.0%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
cyclophosphamide 1.0
treatment_protocol_number 12
chemo 1

protocol 13 15
pCR=-  RFS=15=100.0%  DFS=-  posOutcome=15=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=12=80.0%  LumB=3=20.0%  Normal=0=0.0%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 13
chemo 1

protocol 14 1
pCR=-  RFS=1=100.0%  DFS=-  posOutcome=1=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=100.0%  LumB=0=0.0%  Normal=0=0.0%
docetaxel 1.0
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 14
chemo 1

protocol 15 20
pCR=-  RFS=19=95.0%  DFS=-  posOutcome=19=95.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=19=95.0%  LumB=1=5.0%  Normal=0=0.0%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant unspecified
treatment_protocol_number 15

protocol 16 1
pCR=-  RFS=1=100.0%  DFS=-  posOutcome=1=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=1=100.0%  Normal=0=0.0%
docetaxel 1.0
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 16
chemo 1

protocol 17 4
pCR=-  RFS=3=75.0%  DFS=-  posOutcome=3=75.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=3=75.0%  LumB=1=25.0%  Normal=0=0.0%
methotrexate 1.0
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
cyclophosphamide 1.0
treatment_protocol_number 17
chemo 1

protocol 2 10
pCR=-  RFS=7=70.0%  DFS=-  posOutcome=7=70.0%
Basal=5=50.0%  Her2=4=40.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=1=10.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 2
chemo 1

protocol 3 2
pCR=-  RFS=2=100.0%  DFS=-  posOutcome=2=100.0%
Basal=0=0.0%  Her2=1=50.0%  LumA=1=50.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
doxorubicin 1.0
anti_HER2 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 3
chemo 1

protocol 4 8
pCR=-  RFS=5=62.5%  DFS=-  posOutcome=5=62.5%
Basal=2=25.0%  Her2=0=0.0%  LumA=2=25.0%  LumB=2=25.0%  Normal=2=25.0%
neoadjuvant_or_adjuvant unspecified
treatment_protocol_number 4
no_treatment 1.0

protocol 5 2
pCR=-  RFS=2=100.0%  DFS=-  posOutcome=2=100.0%
Basal=1=50.0%  Her2=0=0.0%  LumA=1=50.0%  LumB=0=0.0%  Normal=0=0.0%
docetaxel 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 5
chemo 1

protocol 6 2
pCR=-  RFS=2=100.0%  DFS=-  posOutcome=2=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=50.0%  LumB=1=50.0%  Normal=0=0.0%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
fluorouracil 1.0
cyclophosphamide 1.0
treatment_protocol_number 6
chemo 1

protocol 7 1
pCR=-  RFS=0=0.0%  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=1=100.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 7
chemo 1

protocol 8 1
pCR=-  RFS=0=0.0%  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=1=100.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 8
chemo 1

protocol 9 1
pCR=-  RFS=1=100.0%  DFS=-  posOutcome=1=100.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=100.0%  LumB=0=0.0%  Normal=0=0.0%
neoadjuvant_or_adjuvant unspecified
anthracycline 1.0
cyclophosphamide 1.0
capecitabine 1.0
treatment_protocol_number 9
epirubicin 1.0
chemo 1


study_20181_GPL96_all-bmc15 53
protocol 1 53
pCR=37=69.8%  RFS=-  DFS=-  posOutcome=37=69.8%
Basal=0=0.0%  Her2=0=0.0%  LumA=39=73.6%  LumB=14=26.4%  Normal=0=0.0%
hormone 1
anti_estrogen 1.0
letrozole 1.0
aromatase_inhibitor 1.0
neoadjuvant_or_adjuvant neo
estrogen_receptor_blocker_and_stops_production 1.0
treatment_protocol_number 1


study_20194_GPL96_all-bmc15 261
protocol 1 156
pCR=43=27.6%  RFS=-  DFS=-  posOutcome=43=27.6%
Basal=36=23.1%  Her2=9=5.8%  LumA=48=30.8%  LumB=50=32.1%  Normal=13=8.3%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
chemo 1

protocol 10 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=100.0%  LumB=0=0.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 10
chemo 1

protocol 11 7
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=1=14.3%  LumA=5=71.4%  LumB=1=14.3%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 11
chemo 1

protocol 12 4
pCR=1=25.0%  RFS=-  DFS=-  posOutcome=1=25.0%
Basal=1=25.0%  Her2=1=25.0%  LumA=2=50.0%  LumB=0=0.0%  Normal=0=0.0%
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
taxane 1.0
treatment_protocol_number 12
chemo 1

protocol 13 9
pCR=2=22.2%  RFS=-  DFS=-  posOutcome=2=22.2%
Basal=1=11.1%  Her2=2=22.2%  LumA=3=33.3%  LumB=3=33.3%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 13
chemo 1

protocol 14 2
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=2=100.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 14
chemo 1

protocol 15 2
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=2=100.0%  Normal=0=0.0%
hormone 1
doxorubicin 1.0
anti_HER2 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 15
chemo 1

protocol 16 2
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=2=100.0%  LumB=0=0.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 16
chemo 1

protocol 17 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=1=100.0%  Normal=0=0.0%
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
letrozole 1.0
aromatase_inhibitor 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
estrogen_receptor_blocker_and_stops_production 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
capecitabine 1.0
treatment_protocol_number 17
chemo 1

protocol 2 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=1=100.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
taxane 1.0
treatment_protocol_number 2
chemo 1

protocol 3 4
pCR=2=50.0%  RFS=-  DFS=-  posOutcome=2=50.0%
Basal=0=0.0%  Her2=4=100.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
doxorubicin 1.0
anti_HER2 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 3
chemo 1

protocol 4 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=1=100.0%
doxorubicin 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
cyclophosphamide 1.0
treatment_protocol_number 4
chemo 1

protocol 5 64
pCR=4=6.2%  RFS=-  DFS=-  posOutcome=4=6.2%
Basal=6=9.4%  Her2=7=10.9%  LumA=31=48.4%  LumB=18=28.1%  Normal=2=3.1%
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 5
epirubicin 1.0
chemo 1

protocol 6 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=1=100.0%  Her2=0=0.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
capecitabine 1.0
treatment_protocol_number 6
chemo 1

protocol 7 3
pCR=1=33.3%  RFS=-  DFS=-  posOutcome=1=33.3%
Basal=0=0.0%  Her2=0=0.0%  LumA=2=66.7%  LumB=0=0.0%  Normal=1=33.3%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 7
chemo 1

protocol 8 1
pCR=0=0.0%  RFS=-  DFS=-  posOutcome=0=0.0%
Basal=0=0.0%  Her2=0=0.0%  LumA=1=100.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
anti_estrogen 1.0
doxorubicin 1.0
aromatase_inhibitor 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
estrogen_receptor_blocker_and_stops_production 1.0
fluorouracil 1.0
anastrozole 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 8
chemo 1

protocol 9 2
pCR=2=100.0%  RFS=-  DFS=-  posOutcome=2=100.0%
Basal=0=0.0%  Her2=2=100.0%  LumA=0=0.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
anti_HER2 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 9
epirubicin 1.0
chemo 1


study_2034_GPL96_all-bmc15 286
protocol 1 286
pCR=-  RFS=179=62.6%  DFS=-  posOutcome=179=62.6%
Basal=50=17.5%  Her2=19=6.6%  LumA=136=47.6%  LumB=74=25.9%  Normal=7=2.4%
radio 1
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1


study_22226_GPL1708_all-bmc15 128
protocol 1 4
pCR=0=0.0%  RFS=2=50.0%  DFS=-  posOutcome=2=50.0%
Basal=1=25.0%  Her2=1=25.0%  LumA=1=25.0%  LumB=0=0.0%  Normal=1=25.0%
doxorubicin 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
chemo 1

protocol 2 111
pCR=27=25.5%  RFS=77=69.4%  DFS=-  posOutcome=82=73.9%
Basal=24=21.6%  Her2=23=20.7%  LumA=55=49.5%  LumB=0=0.0%  Normal=9=8.1%
doxorubicin 1.0
taxaneGeneral 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 2
chemo 1

protocol 3 11
pCR=5=45.5%  RFS=8=72.7%  DFS=-  posOutcome=9=81.8%
Basal=0=0.0%  Her2=5=45.5%  LumA=5=45.5%  LumB=0=0.0%  Normal=1=9.1%
hormone 1
doxorubicin 1.0
taxaneGeneral 1.0
anti_HER2 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 3
chemo 1

protocol 4 2
pCR=0=0.0%  RFS=1=50.0%  DFS=-  posOutcome=1=50.0%
Basal=1=50.0%  Her2=0=0.0%  LumA=1=50.0%  LumB=0=0.0%  Normal=0=0.0%
hormone 1
doxorubicin 1.0
taxaneGeneral 1.0
anti_HER2 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
taxane 1.0
cyclophosphamide 1.0
trastuzumab 1.0
treatment_protocol_number 4
chemo 1


study_22358_GPL5325_all-bmc15 122
protocol 1 95
pCR=10=10.5%  RFS=-  DFS=-  posOutcome=10=10.5%
Basal=20=21.1%  Her2=4=4.2%  LumA=59=62.1%  LumB=2=2.1%  Normal=10=10.5%
docetaxel 1.0
neoadjuvant_or_adjuvant neo
taxane 1.0
capecitabine 1.0
treatment_protocol_number 1
chemo 1

protocol 2 27
pCR=10=37.0%  RFS=-  DFS=-  posOutcome=10=37.0%
Basal=3=11.1%  Her2=11=40.7%  LumA=13=48.1%  LumB=0=0.0%  Normal=0=0.0%
docetaxel 1.0
hormone 1
anti_HER2 1.0
neoadjuvant_or_adjuvant neo
taxane 1.0
capecitabine 1.0
trastuzumab 1.0
treatment_protocol_number 2
chemo 1


study_25055_GPL96_MDACC_M-bmc15 221
protocol 1 221
pCR=43=19.5%  RFS=-  DFS=175=79.2%  posOutcome=178=80.5%
Basal=69=31.2%  Her2=3=1.4%  LumA=76=34.4%  LumB=63=28.5%  Normal=10=4.5%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
chemo 1


study_25065_GPL96_MDACC-bmc15 71
protocol 1 37
pCR=8=21.6%  RFS=-  DFS=31=83.8%  posOutcome=31=83.8%
Basal=10=27.0%  Her2=0=0.0%  LumA=16=43.2%  LumB=10=27.0%  Normal=1=2.7%
doxorubicin 1.0
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
chemo 1

protocol 2 34
pCR=4=11.8%  RFS=-  DFS=28=82.4%  posOutcome=28=82.4%
Basal=8=23.5%  Her2=0=0.0%  LumA=16=47.1%  LumB=7=20.6%  Normal=3=8.8%
docetaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
capecitabine 1.0
treatment_protocol_number 2
epirubicin 1.0
chemo 1


study_25065_GPL96_USO-bmc15 54
protocol 2 54
pCR=19=35.2%  RFS=-  DFS=41=75.9%  posOutcome=44=81.5%
Basal=24=44.4%  Her2=0=0.0%  LumA=14=25.9%  LumB=14=25.9%  Normal=2=3.7%
docetaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
capecitabine 1.0
treatment_protocol_number 2
epirubicin 1.0
chemo 1


study_32646_GPL570_all-bmc15 115
protocol 1 115
pCR=26=22.6%  RFS=-  DFS=-  posOutcome=26=22.6%
Basal=12=10.4%  Her2=24=20.9%  LumA=0=0.0%  LumB=79=68.7%  Normal=0=0.0%
paclitaxel 1.0
neoadjuvant_or_adjuvant neo
anthracycline 1.0
fluorouracil 1.0
taxane 1.0
cyclophosphamide 1.0
treatment_protocol_number 1
epirubicin 1.0
chemo 1


study_9893_GPL5049_all-bmc15 148
protocol 1 114
pCR=-  RFS=76=66.7%  DFS=-  posOutcome=76=66.7%
Basal=1=0.9%  Her2=62=54.4%  LumA=20=17.5%  LumB=30=26.3%  Normal=1=0.9%
radio 1
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 1

protocol 2 34
pCR=-  RFS=20=58.8%  DFS=-  posOutcome=20=58.8%
Basal=0=0.0%  Her2=21=61.8%  LumA=5=14.7%  LumB=8=23.5%  Normal=0=0.0%
estrogen_receptor_blocker 1.0
tamoxifen 1.0
hormone 1
anti_estrogen 1.0
neoadjuvant_or_adjuvant adj
treatment_protocol_number 2


